Explore SDS Optic

inPROBE Technology
inPPROBE^® is a new diagnostic technology combining photonics with molecular biology to detect HER2 expression. This point-of-care solution offers the potential to complement immunohistochemistry (IHC) and genetic testing such as in situ hybridization (ISH) to improve access to targeted therapies.
Explore the technology
Dual-use technologies
We develop photonic coatings for thermal management in buildings and protection of specialist textiles. Explore their potential for civilian and defence applications, and discover how thermoreflective coatings work in an interactive model.
Explore the technology
Antibody manufacturing
We specialize in custom antibody development and small-scale production, offering monoclonal, and anti-idiotype antibody services. With cutting-edge BSL2 labs and expert teams, we provide antigen design, immunization, screening, and purification for innovative diagnostic and therapeutic solutions.
Explore the technology
Optical coatings
We offer advanced lens coating solutions using nanolayer technology to enhance clarity, durability, and performance. Our innovative coatings are applied across various industries such as optics, electronics, and medical devices to improve lens functionality, protection, and longevity for everyday use.
Explore the technology

Our Mission

We are committed to addressing unmet diagnostic and general labolatory needs in oncology and infectious diseases by advancing and optimizing current biomarker technologies. Our mission is to improve patient outcomes by providing innovative, biomarker based diagnostic solutions that benefit patients, healthcare providers, and payors alike.

Corporate video

HER2 biomarker overexpression in cancer

HER2-expressing cancers are a group of aggressive tumors often associated with faster progression and a poorer prognosis. These include breast, gastric, lung and a range of other cancers.

While HER2 positivity can accelerate tumor growth, targeted therapies have significantly improved patient outcomes. Accurate assessment of HER2 status is essential for selecting optimal treatments and advancing precision medicine research.